A Single Arm Study of Brain Metastasis in Patients With HER2-positive Breast Cancer

  • End date
    Jun 3, 2022
  • participants needed
  • sponsor
    Tianjin Medical University Cancer Institute and Hospital
Updated on 3 March 2021


The aim of this study was to evaluate the progression time and efficacy of brain tumors in patients with brain metastases from HER2-positive breast cancer treated with Pyrrolidine and Capecitabine combined with brain radiotherapy.


Brain metastases are very common in HER2-positive breast cancer patients. The vast majority of patients with metastatic brain tumors are in advanced stages of the disease. If not treated in time, the natural course of the disease is extremely short. At present, the main treatment of brain metastases from breast cancer is radiotherapy, combined with chemotherapy and targeted therapy drugs. On the basis of previous clinical studies, the aim of this study was to explore the efficacy and safety of combined brachytherapy with Pyrrotidine and Capecitabine in patients with brain metastases from HER2-positive breast cancer, in order to provide a new, safer and more effective treatment for patients with brain metastases from breast cancer.

Treatment PYRROTINI, Brain radiation therapy
Clinical Study IdentifierNCT04767828
SponsorTianjin Medical University Cancer Institute and Hospital
Last Modified on3 March 2021


Yes No Not Sure

Inclusion Criteria

Signed written informed consent prior to enrollment
Age 18-75 years, female
Patients with pathologically confirmed HER2 expression-positive breast cancer brain metastases; HER2 expression-positive refers to those with a standard immunohistochemical staining (IHC) test showing HER2 as 3+ and/or fluorescence in situ hybridization technique (FISH) positive (confirmed by investigator review at their trial center)
The presence of CNS lesions as confirmed by cranial CT or MRI
ECOG score: 0 to 2
Expected survival of not less than 12 weeks
having received no previous brain radiotherapy or having received brain radiotherapy at the dose specified in the trial protocol
Patients who have been on pyrrolizidine for 3 months after diagnosis of brain metastases and whose disease has not progressed
The function of vital organs meets the following requirements (excluding the use of any blood components and cell growth factors within 14 days)
Routine blood examination criteria need to be met: Hb 100 g/L; ANC 1.5109 /L; PLT 75109 /L B) Biochemical examination should meet the following criteria: TBIL1.5ULN (upper limit of normal); ALT and AST2.5ULN; ALT and AST5ULN if liver metastasis; serum creatinine1.5ULN, creatinine clearance50ml/min (based on Cockroft and Gault formula) C) Cardiac ultrasound; left ventricular ejection fraction (LVEF) 50%
Female patients who are non-surgically sterilized or of childbearing age are required to use a medically approved form of contraception (e.g., IUD, pill, or condom) during and for 3 months after the end of the study treatment period; female patients of childbearing age who are non-surgically sterilized must have a negative serum or urine HCG test within 7 days prior to study enrollment; and must be non-lactating
Subjects are voluntarily enrolled in the study, are compliant, and cooperate with safety and survival follow-up

Exclusion Criteria

Presence of third interstitial fluid that cannot be controlled by drainage or other methods, such as massive pleural and ascites fluid
the presence of multiple factors that interfere with oral administration and absorption of the drug (e.g., inability to swallow, post-gastrectomy, chronic diarrhea, and intestinal obstruction)
have a proven allergy to the drug components of this regimen
Patients who are known to be pregnant or planning to become pregnant, or patients of gestational age who are unwilling to use effective contraception throughout the trial period
Patients with severe concomitant disease or who, in the opinion of the investigator, are not suitable for inclusion
Patients with the presence of meningeal metastases
having participated in a clinical trial of another drug within 4 weeks prior to enrollment
Patients who have used capecitabine during the neoadjuvant/adjuvant phase of therapy are allowed to be enrolled, but those who are ineffective or cannot tolerate capecitabine during the neoadjuvant/adjuvant phase of therapy need to be excluded; patients who have used capecitabine for 3 months after brain metastasis and whose disease has not progressed can be enrolled; other drugs for which the active ingredient is 5-fluorouracil are treated as capecitabine (Note: " used capecitabine" refers to continuous standardized use of capecitabine for 2 cycles)
Concurrently receiving other antitumor therapy
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note